Pharma
Galvus Met (Vildagliptin/Metformin HCl 50 mg/500 mg)
Combination DPP-4 inhibitor and Biguanide; 50mg/500mg Vildagliptin/Metformin tablets for Type 2 Diabetes control.
Galvus Met (Vildagliptin/Metformin HCl 50 mg/500 mg)
Galvus Met is a combination therapy featuring Vildagliptin and Metformin Hydrochloride. Vildagliptin belongs to the DPP-4 inhibitor class, which works by increasing insulin production and decreasing glucagon levels. Metformin is a biguanide that lowers blood sugar by improving the body's response to insulin and reducing liver glucose production. This combination is prescribed for the management of type 2 diabetes mellitus to achieve better glycemic control than monotherapy alone. It should be used alongside a healthy diet and exercise regimen. Not suitable for type 1 diabetes. Common side effects include nausea, stomach upset, and potential hypoglycemia when used with other antidiabetics.
You May Also Like
Combination DPP-4 inhibitor and Biguanide; 50 mg/1000 mg Sitagliptin/Metformin tablets for Type 2 Diabetes management.
Triple antidiabetic combo; Dapagliflozin 10 mg, Sitagliptin 100 mg, and Metformin ER 1000 mg (28 tablets) for Type 2 Diabetes.
Combination DPP-4 inhibitor and Biguanide; 50 mg/500 mg Sitagliptin/Metformin tablets for Type 2 Diabetes management.
Antidiabetic combination; Empagliflozin 12.5 mg and Metformin 1000 mg (28 tablets) for Type 2 Diabetes management.